The rna analysis/ transcriptomics market size has grown rapidly in recent years. It will grow from $8.74 billion in 2025 to $10.22 billion in 2026 at a compound annual growth rate (CAGR) of 16.9%. The growth in the historic period can be attributed to expansion of genomic research programs, increasing adoption of rna sequencing technologies, rising funding for life sciences research, availability of advanced laboratory instruments, growing academic research activity.
The rna analysis/ transcriptomics market size is expected to see rapid growth in the next few years. It will grow to $19.04 billion in 2030 at a compound annual growth rate (CAGR) of 16.8%. The growth in the forecast period can be attributed to increasing demand for precision medicine applications, rising use of transcriptomics in drug discovery, expansion of clinical diagnostics based on gene expression, growing investments in bioinformatics infrastructure, increasing focus on personalized therapeutics. Major trends in the forecast period include increasing adoption of next-generation sequencing platforms, rising use of high-throughput transcriptomic profiling, growing integration of advanced bioinformatics tools, expansion of single-cell rna analysis techniques, enhanced focus on reproducibility and data accuracy.
The growing prevalence of chronic diseases is anticipated to drive the expansion of the RNA analysis/transcriptomics market in the coming years. Chronic diseases are conditions that persist for one year or more, limit daily activities, require continuous medical attention, or involve a combination of these factors. The increasing incidence of such conditions is largely attributed to more sedentary lifestyles, as reduced physical activity negatively affects metabolic health and raises the risk of long-term illnesses. RNA analysis/transcriptomics supports the management of chronic diseases by uncovering changes in gene expression that drive disease progression, allowing for earlier identification, improved diagnostic precision, and the development of targeted, personalized therapies. For example, in January 2025, data released by the Centers for Disease Control and Prevention, a United States-based national public health agency, indicated that an analysis of 2023 national data found approximately 76.4% of U.S. adults, or about 194 million people, had at least one chronic condition, while 51.4% around 131 million adults were living with multiple chronic conditions. The burden differed by age group, with 59.5% of young adults aged 18-34 years, 78.4% of adults aged 35-64 years, and 93% of adults aged 65 years and older reporting one or more chronic conditions in 2023. Consequently, the rising incidence of chronic diseases is contributing to the growth of the RNA analysis/transcriptomics market.
Major companies operating in the RNA analysis/ transcriptomics market are increasing their focus on introducing innovative portfolios to gain a competitive edge in the market. The RNA Portfolio involves the development of new technologies and solutions that are designed to improve the efficiency and effectiveness of RNA analysis. For instance, in May 2023, Twist Bioscience Corporation, a US-based biotechnology company, announced the launch of a portfolio of RNA sequencing tools that contains specific target enrichment capabilities for RNA and whole transcriptome sequencing, as well as the Twist RNA Exome, Twist RNA Library Prep Kit, and Twist Ribosomal RNA (rRNA) and Hemoglobin (Globin) Depletion Kit. The portfolio offers complete workflows for analyzing messenger RNA (mRNA) protein coding sequences, custom targets, and total RNA for the purpose of measuring the transcriptome. Additionally, these goods can be included in the current workflows of their clients.
In August 2024, Danaher Corporation, a United States-based global science and technology company focused on life sciences and diagnostics, completed the acquisition of Genedata AG for an undisclosed consideration. This transaction is intended to enhance Danaher Corporation’s portfolio by incorporating Genedata’s advanced bioinformatics and multi-omics data analysis platforms into its broader range of research and bioprocessing solutions. Genedata is widely recognized as a leading provider of enterprise-scale analytics software for transcriptomics, genomics, and other complex biological datasets, and the acquisition is expected to strengthen Danaher’s capabilities in accelerating biologics discovery, development, and manufacturing. Genedata AG, headquartered in Switzerland, delivers high-throughput data analysis solutions that optimize RNA sequencing workflows and support large-scale omics research for major biopharmaceutical organizations.
Major companies operating in the rna analysis/ transcriptomics market are Affymetrix Inc., Agilent Technologies Inc., Bio-Rad Laboratories Inc., GE Healthcare, Illumina Inc., QIAGEN N.V., F. Hoffmann-La Roche Ltd., Sigma-Aldrich Corporation, Thermo Fisher Scientific Inc., Fluidigm Corporation, Promega Corporation, bioMérieux S.A., CD Genomics Inc., Eurofins Scientific SE, Merck KGaA, Pacific Biosciences of California Inc., Danaher Corporation, Genewiz Inc., Oxford Nanopore Technologies Ltd., BGI Group, Genotypic Technology Pvt. Ltd., MedGenome Labs Pvt. Ltd., Xcelris Labs Ltd., Ocimum Biosolutions Ltd., Strand Life Sciences Pvt. Ltd., SciGenom Labs Pvt. Ltd., Oncocyte Corporation, Tempus Labs Inc., ArcherDX Inc., HTG Molecular Diagnostics Inc.
North America was the largest region in the RNA analysis/transcriptomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rna analysis/ transcriptomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rna analysis/ transcriptomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the RNA analysis and transcriptomics market by increasing costs of imported sequencing instruments, reagents, enzymes, robotic liquid handlers, and high-performance computing hardware. Research institutions and biotechnology companies in North America and Europe are most affected due to dependence on globally sourced consumables and instruments, while Asia-Pacific faces cost pressure on sequencing equipment imports. These tariffs are raising operational expenses and slowing procurement cycles for research labs. However, they are also encouraging local reagent manufacturing, regional instrument assembly, and development of cost-efficient transcriptomic workflows.
The rna analysis/ transcriptomics market research report is one of a series of new reports that provides rna analysis/ transcriptomics market statistics, including rna analysis/ transcriptomics industry global market size, regional shares, competitors with a rna analysis/ transcriptomics market share, detailed rna analysis/ transcriptomics market segments, market trends and opportunities, and any further data you may need to thrive in the rna analysis/ transcriptomics industry. This rna analysis/ transcriptomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Transcriptomics, also known as RNA analysis, is the study of the transcriptome under specific circumstances, environmental conditions, or within specific cells using high-throughput methods.
The main product categories in the RNA analysis/transcriptomics market include reagents/consumables, instruments, and software. These products find applications in various fields, such as clinical diagnostics, drug discovery, toxicogenomics, comparative transcriptomics, and RNA interference. The major technologies involved in RNA analysis/transcriptomics are microarrays, sequencing, polymerase chain reaction, and RNA interference. In clinical diagnostics, RNA analysis is employed to detect different RNA species, pathogen RNA, splice variants, and other elements crucial for disease diagnosis.
The RNA analysis/ transcriptomics market includes revenues earned by entities by providing services such as Whole-Genome Sequencing, Whole-Exome Sequencing, Targeted Sequencing, Microarray Analysis, Sanger Sequencing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The rna analysis/ transcriptomics market size is expected to see rapid growth in the next few years. It will grow to $19.04 billion in 2030 at a compound annual growth rate (CAGR) of 16.8%. The growth in the forecast period can be attributed to increasing demand for precision medicine applications, rising use of transcriptomics in drug discovery, expansion of clinical diagnostics based on gene expression, growing investments in bioinformatics infrastructure, increasing focus on personalized therapeutics. Major trends in the forecast period include increasing adoption of next-generation sequencing platforms, rising use of high-throughput transcriptomic profiling, growing integration of advanced bioinformatics tools, expansion of single-cell rna analysis techniques, enhanced focus on reproducibility and data accuracy.
The growing prevalence of chronic diseases is anticipated to drive the expansion of the RNA analysis/transcriptomics market in the coming years. Chronic diseases are conditions that persist for one year or more, limit daily activities, require continuous medical attention, or involve a combination of these factors. The increasing incidence of such conditions is largely attributed to more sedentary lifestyles, as reduced physical activity negatively affects metabolic health and raises the risk of long-term illnesses. RNA analysis/transcriptomics supports the management of chronic diseases by uncovering changes in gene expression that drive disease progression, allowing for earlier identification, improved diagnostic precision, and the development of targeted, personalized therapies. For example, in January 2025, data released by the Centers for Disease Control and Prevention, a United States-based national public health agency, indicated that an analysis of 2023 national data found approximately 76.4% of U.S. adults, or about 194 million people, had at least one chronic condition, while 51.4% around 131 million adults were living with multiple chronic conditions. The burden differed by age group, with 59.5% of young adults aged 18-34 years, 78.4% of adults aged 35-64 years, and 93% of adults aged 65 years and older reporting one or more chronic conditions in 2023. Consequently, the rising incidence of chronic diseases is contributing to the growth of the RNA analysis/transcriptomics market.
Major companies operating in the RNA analysis/ transcriptomics market are increasing their focus on introducing innovative portfolios to gain a competitive edge in the market. The RNA Portfolio involves the development of new technologies and solutions that are designed to improve the efficiency and effectiveness of RNA analysis. For instance, in May 2023, Twist Bioscience Corporation, a US-based biotechnology company, announced the launch of a portfolio of RNA sequencing tools that contains specific target enrichment capabilities for RNA and whole transcriptome sequencing, as well as the Twist RNA Exome, Twist RNA Library Prep Kit, and Twist Ribosomal RNA (rRNA) and Hemoglobin (Globin) Depletion Kit. The portfolio offers complete workflows for analyzing messenger RNA (mRNA) protein coding sequences, custom targets, and total RNA for the purpose of measuring the transcriptome. Additionally, these goods can be included in the current workflows of their clients.
In August 2024, Danaher Corporation, a United States-based global science and technology company focused on life sciences and diagnostics, completed the acquisition of Genedata AG for an undisclosed consideration. This transaction is intended to enhance Danaher Corporation’s portfolio by incorporating Genedata’s advanced bioinformatics and multi-omics data analysis platforms into its broader range of research and bioprocessing solutions. Genedata is widely recognized as a leading provider of enterprise-scale analytics software for transcriptomics, genomics, and other complex biological datasets, and the acquisition is expected to strengthen Danaher’s capabilities in accelerating biologics discovery, development, and manufacturing. Genedata AG, headquartered in Switzerland, delivers high-throughput data analysis solutions that optimize RNA sequencing workflows and support large-scale omics research for major biopharmaceutical organizations.
Major companies operating in the rna analysis/ transcriptomics market are Affymetrix Inc., Agilent Technologies Inc., Bio-Rad Laboratories Inc., GE Healthcare, Illumina Inc., QIAGEN N.V., F. Hoffmann-La Roche Ltd., Sigma-Aldrich Corporation, Thermo Fisher Scientific Inc., Fluidigm Corporation, Promega Corporation, bioMérieux S.A., CD Genomics Inc., Eurofins Scientific SE, Merck KGaA, Pacific Biosciences of California Inc., Danaher Corporation, Genewiz Inc., Oxford Nanopore Technologies Ltd., BGI Group, Genotypic Technology Pvt. Ltd., MedGenome Labs Pvt. Ltd., Xcelris Labs Ltd., Ocimum Biosolutions Ltd., Strand Life Sciences Pvt. Ltd., SciGenom Labs Pvt. Ltd., Oncocyte Corporation, Tempus Labs Inc., ArcherDX Inc., HTG Molecular Diagnostics Inc.
North America was the largest region in the RNA analysis/transcriptomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rna analysis/ transcriptomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rna analysis/ transcriptomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the RNA analysis and transcriptomics market by increasing costs of imported sequencing instruments, reagents, enzymes, robotic liquid handlers, and high-performance computing hardware. Research institutions and biotechnology companies in North America and Europe are most affected due to dependence on globally sourced consumables and instruments, while Asia-Pacific faces cost pressure on sequencing equipment imports. These tariffs are raising operational expenses and slowing procurement cycles for research labs. However, they are also encouraging local reagent manufacturing, regional instrument assembly, and development of cost-efficient transcriptomic workflows.
The rna analysis/ transcriptomics market research report is one of a series of new reports that provides rna analysis/ transcriptomics market statistics, including rna analysis/ transcriptomics industry global market size, regional shares, competitors with a rna analysis/ transcriptomics market share, detailed rna analysis/ transcriptomics market segments, market trends and opportunities, and any further data you may need to thrive in the rna analysis/ transcriptomics industry. This rna analysis/ transcriptomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Transcriptomics, also known as RNA analysis, is the study of the transcriptome under specific circumstances, environmental conditions, or within specific cells using high-throughput methods.
The main product categories in the RNA analysis/transcriptomics market include reagents/consumables, instruments, and software. These products find applications in various fields, such as clinical diagnostics, drug discovery, toxicogenomics, comparative transcriptomics, and RNA interference. The major technologies involved in RNA analysis/transcriptomics are microarrays, sequencing, polymerase chain reaction, and RNA interference. In clinical diagnostics, RNA analysis is employed to detect different RNA species, pathogen RNA, splice variants, and other elements crucial for disease diagnosis.
The RNA analysis/ transcriptomics market includes revenues earned by entities by providing services such as Whole-Genome Sequencing, Whole-Exome Sequencing, Targeted Sequencing, Microarray Analysis, Sanger Sequencing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. RNA Analysis/ Transcriptomics Market Characteristics
3. RNA Analysis/ Transcriptomics Market Supply Chain Analysis
4. Global RNA Analysis/ Transcriptomics Market Trends and Strategies
5. RNA Analysis/ Transcriptomics Market Analysis of End Use Industries
7. Global RNA Analysis/ Transcriptomics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global RNA Analysis/ Transcriptomics Total Addressable Market (TAM) Analysis for the Market
9. RNA Analysis/ Transcriptomics Market Segmentation
10. RNA Analysis/ Transcriptomics Market Regional and Country Analysis
11. Asia-Pacific RNA Analysis/ Transcriptomics Market
12. China RNA Analysis/ Transcriptomics Market
13. India RNA Analysis/ Transcriptomics Market
14. Japan RNA Analysis/ Transcriptomics Market
15. Australia RNA Analysis/ Transcriptomics Market
16. Indonesia RNA Analysis/ Transcriptomics Market
17. South Korea RNA Analysis/ Transcriptomics Market
18. Taiwan RNA Analysis/ Transcriptomics Market
19. South East Asia RNA Analysis/ Transcriptomics Market
20. Western Europe RNA Analysis/ Transcriptomics Market
21. UK RNA Analysis/ Transcriptomics Market
22. Germany RNA Analysis/ Transcriptomics Market
23. France RNA Analysis/ Transcriptomics Market
24. Italy RNA Analysis/ Transcriptomics Market
25. Spain RNA Analysis/ Transcriptomics Market
26. Eastern Europe RNA Analysis/ Transcriptomics Market
27. Russia RNA Analysis/ Transcriptomics Market
28. North America RNA Analysis/ Transcriptomics Market
29. USA RNA Analysis/ Transcriptomics Market
30. Canada RNA Analysis/ Transcriptomics Market
31. South America RNA Analysis/ Transcriptomics Market
32. Brazil RNA Analysis/ Transcriptomics Market
33. Middle East RNA Analysis/ Transcriptomics Market
34. Africa RNA Analysis/ Transcriptomics Market
36. RNA Analysis/ Transcriptomics Market Competitive Landscape and Company Profiles
37. RNA Analysis/ Transcriptomics Market Other Major and Innovative Companies
40. RNA Analysis/ Transcriptomics Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
RNA Analysis/ Transcriptomics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses rna analysis/ transcriptomics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for rna analysis/ transcriptomics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The rna analysis/ transcriptomics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Reagents/Consumables; Instruments; Software2) By Technology; Microarrays; Sequencing; Polymerase Chain Reaction
3) By Application: Clinical Diagnostics; Drug Discovery; Toxicogenomics; Comparative Transcriptomics; RNA Interference
Subsegments:
1) By Reagents/Consumables: Nucleotides; Enzymes; Buffers and Solutions; Sample Preparation Kits; Sequencing Kits2) By Instruments: Sequencers; Real-Time PCR Machines; Microarrays; Electrophoresis Systems; Robotic Liquid Handlers
3) By Software: Data Analysis Software; Bioinformatics Tools; Statistical Analysis Software; Visualization Software; Database Management Systems
Companies Mentioned: Affymetrix Inc.; Agilent Technologies Inc.; Bio-Rad Laboratories Inc.; GE Healthcare; Illumina Inc.; QIAGEN N.V.; F. Hoffmann-La Roche Ltd.; Sigma-Aldrich Corporation; Thermo Fisher Scientific Inc.; Fluidigm Corporation; Promega Corporation; bioMérieux S.A.; CD Genomics Inc.; Eurofins Scientific SE; Merck KGaA; Pacific Biosciences of California Inc.; Danaher Corporation; Genewiz Inc.; Oxford Nanopore Technologies Ltd.; BGI Group; Genotypic Technology Pvt. Ltd.; MedGenome Labs Pvt. Ltd.; Xcelris Labs Ltd.; Ocimum Biosolutions Ltd.; Strand Life Sciences Pvt. Ltd.; SciGenom Labs Pvt. Ltd.; Oncocyte Corporation; Tempus Labs Inc.; ArcherDX Inc.; HTG Molecular Diagnostics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this RNA Analysis/ Transcriptomics market report include:- Affymetrix Inc.
- Agilent Technologies Inc.
- Bio-Rad Laboratories Inc.
- GE Healthcare
- Illumina Inc.
- QIAGEN N.V.
- F. Hoffmann-La Roche Ltd.
- Sigma-Aldrich Corporation
- Thermo Fisher Scientific Inc.
- Fluidigm Corporation
- Promega Corporation
- bioMérieux S.A.
- CD Genomics Inc.
- Eurofins Scientific SE
- Merck KGaA
- Pacific Biosciences of California Inc.
- Danaher Corporation
- Genewiz Inc.
- Oxford Nanopore Technologies Ltd.
- BGI Group
- Genotypic Technology Pvt. Ltd.
- MedGenome Labs Pvt. Ltd.
- Xcelris Labs Ltd.
- Ocimum Biosolutions Ltd.
- Strand Life Sciences Pvt. Ltd.
- SciGenom Labs Pvt. Ltd.
- Oncocyte Corporation
- Tempus Labs Inc.
- ArcherDX Inc.
- HTG Molecular Diagnostics Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 10.22 Billion |
| Forecasted Market Value ( USD | $ 19.04 Billion |
| Compound Annual Growth Rate | 16.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
